Ivermectin is a versatile antiparasitic medication widely used to treat a variety of parasitic infections in humans. It is particularly effective against conditions such as onchocerciasis (river blindness), strongyloidiasis, ascariasis, and filariasis. For onchocerciasis, a single dose of 150 mcg/kg can significantly reduce the number of microfilariae in the skin and eye, providing long-term relief. In the case of strongyloidiasis, ivermectin is administered at a dosage of 200 mcg/kg, often in two doses, to effectively eliminate the Strongyloides stercoralis parasite. The drug’s efficacy in treating these infections has made it a cornerstone in global health initiatives aimed at combating neglected tropical diseases.
In addition to its primary uses, Human Ivermectin is also employed to treat ectoparasitic infections such as scabies and lice. For scabies, a single oral dose of 200 mcg/kg is typically recommended, while for head lice, topical formulations of ivermectin are available. The drug works by binding to specific ion channels in the parasites, leading to paralysis and death. Its broad-spectrum activity and favorable safety profile have made ivermectin an essential tool in public health, particularly in mass drug administration programs targeting vulnerable populations in endemic regions. Despite its effectiveness, it is important to use ivermectin responsibly and under medical guidance to avoid potential side effects and ensure optimal treatment outcomes.